Lansoprazole Ranbaxy (Uk) (Lansoprazole)

Lansoprazole belongs to the proton pump inhibitor class. It binds irreversibly to the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the secretory surface of parietal cells. By inhibiting this enzyme, it blocks the final step of acid production, leading to a significant reduction in both basal and stimulated gastric acid output.

The appropriate dose of Lansoprazole Ranbaxy is determined by a qualified prescriber based on the specific indication, patient characteristics, and clinical response. Healthcare professionals consider factors such as disease severity, renal and hepatic function, and concomitant medications when selecting the dosage regimen.

Safety data for Lansoprazole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in breast milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lansoprazole, as a proton pump inhibitor, provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, its efficacy is comparable, though individual response and drug‑interaction profiles may differ. Choice of therapy often depends on patient tolerance, drug‑interaction potential, and clinical guidelines.

Lansoprazole Ranbxy should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Lansoprazole is taken orally, usually as a tablet, with a glass of water. It is generally recommended to swallow the tablet whole, preferably before a meal, to ensure optimal absorption and acid‑suppression effect. Patients should follow the prescriber’s instructions regarding timing and frequency.

Serious but rare risks include severe skin reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, liver injury, anaphylaxis, interstitial nephritis, and increased risk of bone fractures with long‑term therapy. Patients should seek immediate medical attention if they experience symptoms like rash, severe abdominal pain, jaundice, or unexplained swelling.

Lansoprazole is contraindicated in individuals with known hypersensitivity to lansoprazole or any component of the formulation. Caution is advised for patients with severe hepatic impairment, those on medications with major interactions (e.g., clopidogrel), and patients with a history of certain rare adverse reactions. A healthcare professional should evaluate suitability before initiating therapy.